News|Videos|November 2, 2023
Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)
Author(s)Joseph Gligorov, MD, PhD
Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.
Advertisement
Episodes in this series
Advertisement
Related to this article
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
Advertisement
Advertisement
Trending on OncLive
1
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
2
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
3
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
4
VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous Cancers
5